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The encapsulation of porcine islets is an attractive methodology for the treatment of Type I diabetes. In the current study, the
use of pravastatin as a mild anti-inflammatory agent was investigated in pancreatectomized diabetic canines transplanted with
porcine islets encapsulated in agarose-agarose macrobeads and given 80 mg/day of pravastatin (𝑛 = 3) while control animals did
not receive pravastatin (𝑛 = 3). Control animals reached preimplant insulin requirements on days 18, 19, and 32. Pravastatintreated animals reached preimplant insulin requirements on days 22, 27, and 50. Two animals from each group received a second
macrobead implant: control animals remained insulin-free for 15 and 21 days (AUC = 3003 and 5078 mg/dL/24 hr days 1 to 15) and
reached preimplant insulin requirements on days 62 and 131. Pravastatin treated animals remained insulin-free for 21 and 34 days
(AUC = 1559 and 1903 mg/dL/24 hr days 1 to 15) and reached preimplant insulin requirements on days 38 and 192. Total incidence
(83.3% versus 64.3%) and total severity (22.7 versus 18.3) of inflammation on tissue surfaces were higher in the control group at
necropsy. These findings support pravastatin therapy in conjunction with the transplantation of encapsulated xenogeneic islets for
the treatment of diabetes mellitus.

1. Introduction
Type 1 diabetic patients face a lifetime of daily insulin
injections due to destruction of the insulin-producing islets
of Langerhans within the pancreas. Alternatively, whole
pancreas or the islets alone, after isolation from the pancreas, can be transplanted to the patient. Transplantation of
either the pancreas or the islets, however, requires a lifetime
of immunosuppressive therapy. One possible solution to
avoid lifelong immunosuppression is to encapsulate the islets
within a semipermeable membrane. The rationale behind this
strategy is to protect the islets from destruction by immune
cells and immune mediators such as cytokines. The porous

membrane should allow the diffusion of insulin and other
peptides out of the encapsulation device while still permitting
nutrient exchange to support the islet cells.
Following the seminal studies of Lim and Sun [1] in
which encapsulated rat islets were shown to restore normoglycemia in diabetic rats, many groups have attempted islet
grafting using large animal models as a prelude to clinical
trials. Warnock and Rajotte demonstrated the applicability
of nonencapsulated islet transplantation in dogs with longterm function of islets autografted to either the spleen or
liver [2]. Allogeneic islet transplantation within intravascular
devices has also been successful. Sullivan et al. reported 6
of 10 pancreatectomized dogs without exogenous insulin for
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up to 5 months following the grafting of such devices seeded
with allogeneic islets [3]. Brunetti et al. used an intravascular device to at least partially reverse hyperglycemia in
spontaneously diabetic dogs grafted with xenogeneic porcine
islets [4]. A similar intravascular device study in pancreatectomized dogs that received porcine islets was reported by
Maki et al. in which 7 of 17 dogs were maintained on reduced
insulin requirements for 53–114 days while 2 animals received
reduced insulin for 218 and 263 days [5]. Thrombosis of the
vascular shunt, however, remains an ongoing concern for
such devices.
To avoid such complications associated with intravascular devices and to limit immunosuppression, many
researchers have turned to transplanting encapsulated islets
into the peritoneal cavity as free-floating diffusion structures.
Soon-Shiong et al. demonstrated 63–172 days of insulinindependence with allogeneic islets microencapsulated in
alginate and transplanted into the peritoneal cavity of spontaneously diabetic dogs receiving subtherapeutic doses of
cyclosporine [6]. Similarly, reduced insulin requirements
and/or insulin independence was reported by Lanza et
al. using XM-50 tubular membranes in the absence of
immunosuppression [7]. This group later reported insulinindependence for 60 to >175 days in 4 spontaneously diabetic
dogs using alginate encapsulated canine islets on low-dose
cyclosporine therapy [8]. More recently, Wang et al. were able
to discontinue exogenous insulin therapy in 8 of 9 pancreatectomized canines for 64–106 days and in one animal for
214 days using allogeneic islets encapsulated in a triple membrane alginate-based bead without any immunosuppression
or anti-inflammatory treatment [9]. Kin et al. demonstrated
insulin independence for 6–119 days in pancreatectomized
dogs receiving xenogeneic porcine islets encapsulated in
agarose and polystyrene sulfonic acid [10]. A bioartificial
endocrine pancreas consisting of porcine islets contained in
an agarose matrix within semipermeable membranes was
also shown to reduce insulin requirements in pancreatectomized dogs for up to 17 weeks [11].
We have reported on the ability of porcine islets encapsulated in a double layer of agarose to eliminate insulin
requirements in 12 of 12 spontaneously diabetic BB rats
for more than 200 days [12]. In these studies, no immunosuppression was required and the rats remained healthy
throughout the study. With a view to clinical trials, we set
out to determine the efficacy of agarose-agarose porcine
islet macrobead implantation in a large animal model of
diabetes mellitus. In the current study, we demonstrate
improved functionality and biocompatibility of porcine islet
macrobeads in pancreatectomized dogs and administered the
HMG-CoA reductase inhibitor pravastatin for its mild antiinflammatory properties [13] as compared to diabetic dogs
that did not receive pravastatin.

2. Materials and Methods
2.1. Animals. A total of six male devocalized Beagle dogs
(Ridgelan Farms, Inc.) were received at approximately 25
weeks of age. The dogs were individually housed in stainless
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steel cages, 32 W × 42 L × 32 H, with rubbercoated mesh
flooring and a stainless steel platform, 32 × 40 . Science Diet
Growth (Hill’s, 6730) was given to the animals twice daily.
Clean municipal water was provided ad libitum. Viokase
(Henry Schein, 9758341) powder was added to food at a dose
of 1 tsp/meal following pancreatectomy. The temperature
of the room was maintained within 18–28∘ C with relative
humidity of 30–70%. A 12 hour light cycle was maintained
throughout the study with lights on at 0700 hours. All study
protocol procedures were approved by The Rogosin Institute
Animal Care and Use Committee (IACUC). The Rogosin
Institute-Xenia Division animal facility holds Full Accreditation status awarded by the Association for Assessment
and Accreditation of Laboratory Animal Care, International
(AAALAC, Int.).
2.2. Isolation of Porcine Islets and Production of Porcine Islet
Macrobeads. Donor islets were prepared from Newsham
sows over two years of age and with multiple parities. After
electrical stun and exsanguination (Bob Evans Farms, Xenia,
OH), pancreata were retrieved and transported to the islet
isolation laboratory in cold Hank’s Balanced Salt Solution
(HBSS; Mediatech, 21-020) on ice. Warm ischemia times
averaged 14.43 minutes while cold ischemia times ranged
from 30 minutes to one hour. Islet isolation was carried
out as previously described [14]. Briefly, after trimming the
gland of fat and connective tissue, the main pancreatic
duct was cannulated and injected with HBSS containing
collagenase V (Sigma Aldrich, C9263) at a concentration
of 1.8 g/L, and protamine (Sigma Aldrich, P4005) at a
concentration of 0.06 g/L. Four times the gram weight of
the pancreas (in mL) was perfused through the pancreatic
duct at a rate of 150 mL/min at 18∘ C. Islets were purified
on discontinuous Eurocollins (Mediatech, 99-408)—Ficoll
(Sigma Aldrich, F9378) gradients of densities 1.105 g/cm3 ,
1.095 g/cm3 , and 1.055 g/cm3 in 50 mL polystyrene conical
tubes. The tubes were centrifuged at 2000 RPM, and isletcontaining layers were manually collected. 500 islet equivalents were encapsulated in each agarose-agarose macrobead
as previously described [14]. Islet macrobeads were maintained in RPMI containing 2.5% porcine serum (Mediatech,
35-041) and 1% antibiotic/antimycotic (A/A; Gibco Life
Technologies, 15240) in an atmosphere of 4–6% CO2 and
air at 36–38∘ C. Macrobeads were examined for uniformity,
collected the day prior to implant and were aliquoted to
175 mL conical tubes. A maximum of 400 macrobeads per
tube were stored overnight at room temperature (19–27∘ C)
in RPMI (Gibco Life Technologies, 22400) containing 1%
A/A.
2.3. Microbiology Screening of Macrobeads for Implantation.
Four weeks prior to islet macrobead implantation, representative samples of macrobeads and culture media were sent
to LabCorp (Columbus, OH) for bacterial and fungal testing (Bioburden Process). The macrobeads were aseptically
crushed (culture media tested as supplied) and supernatant
cultured on Sabouraud and Mycosel media (28 days) and
blood and MacConkey Agar (48 hr).
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Table 1: Individual dog insulin requirements and islet macrobead information at first and second implant.
Porcine islet macrobead Information

Control
First
implant
Pravastatin

Control
Second
implant
Pravastatin

Animal ID

Body
weight
(kg)

Daily insulin
requirement
(IU)

Daily insulin
production
(IU/bead)

Number of
macrobeads
implanted

Total daily insulin
(IU) from implanted
macrobeads

Weight of
implanted
macrobeads
(kg)

UYL-0
TSL-0
ORL-0
VPL-0
UDL-0
UVL-0

12.88
11.48
11.11
11.61
11.39
12.79

15
16
20
17
14
22

0.0378
0.0378
0.0378
0.0378
0.0378
0.0378

736
788
981
835
786
1079

27.82
29.79
37.08
31.56
29.71
40.79

0.195
0.207
0.256
0.219
0.205
0.285

UYL-0
TSL-0
ORL-0
VPL-0
UDL-0
UVL-0

12.93
12.20
11.20
12.11
10.98
12.93

15
18
18
22
13
26

0.0382
0.0382
—
0.0382
0.0382
—

1065
1278
—
1565
923
—

40.68
48.82
—
59.78
32.26
—

0.286
0.343
—
0.415
0.245
—

2.4. Surgical Procedures. Animals were sedated with acepromazine at a dose of 0.05 mg/kg IM (Henry Schein,
356-7290) and anesthetized with ketamine at a dose of
5 mg/kg (Fort Dodge Animal Health, 9952949), diazepam
at a dose of 1 mg/kg (Butler, GNR04054), and isoflurane
gas at 1–3% (Henry Schein, 982-2413). During surgery
all animals received buprenorphine (Butler, GNR02300) at
doses of 0.005–0.020 mg/kg IM during surgery and every 8–
12 hours postsurgery, continuing for 2-3 days; and cefotaxime
(claforan antibiotic; Henry Schein, 852-1633) at a dose of
20 mg/kg IV during and 8 hours postsurgery. At implant,
the abdominal, subcutaneous, and cutaneous incisions were
closed with 3–0 vicryl (Ethicon, J333), 3–0 vicryl, and 3–0
nylon (Ethicon, J669) sutures, respectively. At pancreatectomy, the abdominal, subcutaneous, and cutaneous incisions
were closed with 2–0 vicryl (Ethicon, J332), 4–0 polymend
(Veterinary Products Laboratories, V-397-1), and 3–0 nylon
(Ethicon, J669H) sutures, respectively.
Seven weeks following arrival, all animals, with the
exception of VPL-0, underwent pancreatectomy for the
induction of insulin-dependent diabetes. VPL-0 replaced
an unsuitable study animal during week three and was
therefore pancreatectomized at four weeks after arrival. The
pancreas was exposed by a peritoneal midline incision,
approximately 5–8 cm long. The pancreas was removed
with blunt dissection, and the site of pancreatectomy was
photographed. At the time of pancreatectomy, the majority
of the omentum was also removed. Following induction,
animals were maintained on Humulin 70/30 insulin (Eli Lilly,
029363) at doses to attempt morning (0900 hr) and evening
(1800 hr) normoglycemia. Exogenous insulin therapy was
provided following pancreatectomy and was also resumed
postmacrobead implantation when a consistent increase in
blood glucose above normoglycemia was observed for at least
3 days.

2.5. Porcine Islet Macrobead Implantations. Porcine islet macrobeads were implanted into the peritoneal cavities of all
six animals 26 weeks following pancreatectomy, at a dose of
1.85 × total daily exogenous insulin requirements. Fifteen
weeks following the initial macrobead implant, a second
implant of porcine islet macrobeads was performed in four of
the six animals at a dose of 2.71 × total daily exogenous insulin
requirements. Pravastatin (80 mg/day, Teva Pharmaceuticals)
was administered beginning on the day of islet macrobead
implantation and was continued, daily, throughout the course
of the study.
Because the in vivo environment of the dog abdomen
would likely impair insulin production from implanted
macrobeads as compared to the carefully controlled in vitro
culture environment, we opted to implant dogs with enough
macrobeads to provide 1.85 times (1.85 × dose for the 1st
implant) or 2.71 times (2.71 × dose for the 2nd implant) the
amount of each dog’s daily exogenous insulin requirement.
Once a week prior to macrobead implantation, insulin
production during a 24-hour period of in vitro culture was
determined for each batch of islet macrobeads. For implant
purposes, the average daily insulin secretion per macrobead
in the four weeks prior to each implant was considered
(Table 1). The daily exogenous insulin requirements of each
macrobead implanted dog were multiplied by 1.85 (first
implant) or 2.71 (second implant) and enough macrobeads
were implanted to provide the desired dose of insulin.
Since insulin production varies with every batch of islet
macrobeads, each preparation of islet macrobeads was evenly
divided amongst the different recipient dogs such that each
animal received a proportion of each batch of macrobeads
based on exogenous insulin requirements (Table 1). For the
first implant, each dog received 737–1081 porcine islet macrobeads with a total macrobead weight of 195.2–285.9 g. For
the second macrobead implant each dog received 923–1565

4
porcine islet macrobeads weighing 244.7–415.0 g. Average
macrobead age (time postisolation and encapsulation) was
12 weeks for all dogs at the time of the first implant and
10 weeks for the second implant.
A peritoneal midline incision was made and the site
of pancreatectomy was examined for the presence of any
residual pancreatic tissue just prior to placing the macrobeads
into the peritoneal cavity. Immediately prior to implant,
macrobeads were washed three times with RPMI containing
1% A/A and were gently placed into the peritoneal cavity
by use of a sterile plastic spoon. As needed, animals were
manually fed Hill’s Prescription Diet A/D (5670), Hill’s
canned Science Diet Growth (6680), and/or Nutri-Cal (Evsco
Pharmaceuticals, 01311) to maintain normoglycemia during
the first 24–48 hr postimplant.
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stained with haematoxylin and eosin (H&E). Samples were
analyzed by a board-certified pathologist and the macroscopic and histopathological findings were documented.
All histopathology was performed according to standard
operating procedures of PAI.

3. Results

2.8. Necropsy. Complete necropsies were performed
29 weeks following a second implant of porcine islet
macrobeads. Following anesthesia and collection of blood
and exsanguinations, macrobeads were randomly selected
for histopathology. Macroscopic observations were noted
and major organ systems and tissues were photographed.
Weights of major organs were recorded. Tissue samples,
including porcine islet macrobeads, were either aliquoted
to frozen storage (−70∘ C) or fixed in 10% neutral buffered
formalin and sent to Pathology Associates International
(PAI, A Charles River Company) for histopathology.

3.1. Insulin Requirements and Individual Blood Glucose.
Following the first macrobead implantation, all animals
remained insulin-free for a period of nine days despite the
implantation of a suboptimal critical mass of islet tissue
(Figure 1). On the tenth day following macrobead implantation, all six animals were started on exogenous insulin
therapy in response to rising blood glucose levels. Insulin
requirements gradually increased to preimplant levels over
the following 8–40 days. Non-pravastatin-treated animals
reached preimplant insulin requirements on days 18, 19,
and 32 while pravastatin-treated animals reached preimplant
insulin requirements on days 22, 27, and 50 following the
implant.
Following the second islet macrobead implant, the two
non-pravastatin-treated dogs (UYL-0 and TSL-0) began
exogenous insulin therapy on days 16 and 21, respectively
(Figure 1(a)). Before second implant, insulin requirements
for the non-pravastatin-treated dogs were reached on days
62 and 131. The two pravastatin-treated animals (UDL0 and VPL-0) began insulin therapy on days 21 and 34,
respectively. Before second implant, insulin requirements for
these dogs were reached on days 38 and 192 (Figure 1(b)).
A more gradual return to preimplant insulin requirements
was observed for both groups of animals following the
second macrobead implant, although a suboptimal dose
of islet tissue was again transplanted. Using the total area
under the curve with respect to ground [15], the glucose area under the curve (AUC) was calculated for the
period of time that all four of these animals remained
insulin-free (day 1 to 15 after the second implant). The
two pravastatin-treated animals, UDL-0 and VPL-0, had an
AUC of 1559 mg/dL/24 hr and 1903 mg/dL/24 hr, respectively.
The AUC for the non-pravastatin-treated animals, TSL-0
and UYL-0, was 3003 mg/dL/24 hr and 5078 mg/dL/24 hr,
respectively (𝑃 = 0.15 between groups, two-tailed t-test).
Importantly, normoglycemia was maintained throughout
most of the insulin-free period for both groups of animals
(Figure 1).

2.9. Histopathology. At the time of pancreatectomy, both
pancreas and omentum were fixed in 10% neutral buffered
formalin for 24 hr at which time tissues were washed and
stored in 70% ETOH. At necropsy, the following tissues
were collected, fixed as above, and sent for histopathology: heart, spleen, liver, kidneys, brain, testes, duodenum,
jejunum, ileum, mesentery, adrenal glands, stomach, lungs,
diaphragm, abdominal musculature, bone (sternum), spinal
cord, sciatic nerve, epididymis, eyes, submandibular lymph
nodes, popliteal lymph nodes, and mesenteric lymph nodes.
Tissues were embedded in paraffin, and 5 𝜇m sections were

3.2. IVGTT. Individual blood glucose levels taken during
IVGTTs are presented in Figure 2. Prior to the surgical
induction of diabetes, all animals reached a peak glucose
level by 2 minutes after the infusion of dextrose which then
returned to baseline levels by 2 hours. Following pancreatectomy, baseline hyperglycemia was noted in five of the six
study animals. One animal, UYL-0, demonstrated a similar
response as to preinduction dextrose challenge (Figure 2(a)).
All animals were receiving insulin therapy at this time.
Nineteen to twenty days following the second macrobead implant, all study animals were again challenged.

2.6. Clinical Observations. Individual animal medical observations were recorded daily throughout the study. Blood
glucose was initially determined using Accu-chek advantage
blood glucose monitor and Chemstrips (Roche Diagnostics)
and had a maximum value of 500 mg/dL. Later in the
study Accu-Chek Simplicity BG monitor and Chemstrips
(Roche Diagnostics) were used and had a maximum value
of 600 mg/dL. Intravenous glucose tolerance tests (IVGTTs;
50% dextrose in sterile water, 1.0 g dextrose/kg) were also
performed throughout the study.
2.7. Porcine Insulin and C-Peptide Assays. Standard radioimmunoassays, from Linco Research, Inc., were used for the
detection of porcine insulin (PI-12K, sensitivity of 2 𝜇U/mL)
and porcine C-peptide (PCP-22K, sensitivity of 0.1 ng/mL).
Assays were run with samples in duplicate and reference,
standards, and controls in triplicate according to the manufacturer’s instructions.
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Figure 1: Blood glucose levels of study animals are shown as an average of daily AM and PM blood glucose levels (open circles). Exogenous
insulin totals are graphed as a sum of daily AM and PM insulin units received (closed squares). Macrobead recipients that did not receive
pravastatin (control animals) are shown in panel (a) (UYL-0, TSL-0, and ORL-0). Macrobead recipients that received daily pravastatin
(80 mg/day) are shown in panel (b) (VPL-0, UDL-0, and UVL-0). ORL-0 and UVL-0 did not receive a second porcine islet macrobead
implant.

Both non-pravastatin-treated animals returned to prechallenge blood glucose levels, although hyperglycemia was
still present four hours after the procedure. One of these
animals, UYL-0, began insulin therapy five days prior,
making interpretation difficult. The other non-pravastatintreated dog, TSL-0, was not receiving exogenous insulin
and demonstrated some ability to respond to a glucose
challenge and return to a prechallenge blood glucose level.
Although neither of the two animals on pravastatin received
exogenous insulin therapy at the time of the IVGTT following the second implant, both animals demonstrated
a significant glucose response as prechallenge levels were
reestablished. One animal, VPL-0, demonstrated the notable
ability to return to prechallenge normoglycemia, although
this response was slower than preinduction (2 hours versus
30 minutes, Figure 2(b)). The two pravastatin-treated animals, UDL-0 and VPL-0, had an AUC of 47,541 mg/dL/min
and 21,462 mg/dL/min, respectively. The AUC for the
non-pravastatin-treated animals, TSL-0 and UYL-0, was
52,321 mg/dL/min and 57,589 mg/dL/min, respectively (𝑃 =
0.264, two-tailed t-test). Because VPL-0 was able to return
to prechallenge normoglycemia by 120 minutes postdextrose
administration (and therefore blood glucose measurements
for VPL-0 were not taken beyond that point), only this time

period (0 minutes to 120 minutes) was considered for the
glucose AUC calculations for all animals.
3.3. Body Weights. All animals lost body weight immediately after pancreatectomy (Figure 3). Over the next several months, all animals regained weight and surpassed
preinduction weights. At the time of the first macrobead
implant an average weight gain of 1.76 kg was observed.
A slight increase in body weight is also observed in the
immediate period following both macrobead implantations,
as a result of macrobead weight and fluid therapy associated
with the surgical procedures. No significant differences in
body weights were observed between pravastatin and nonpravastatin-treated animals.
3.4. Blood Chemistry and Complete Blood Count. Complete
blood biochemical tabulated profiles are provided as Supplementary Figure S1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2014/405362. Average glycosylated hemoglobin was high throughout the study for
both groups of dogs following pancreatectomy. Average
fructosamine levels, however, were in the normal range
throughout the study for both groups of animals. There were
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Figure 2: Blood glucose levels during IVGTTs at time = 2, 5, 10, 15, 30, 60, 90, 120, and 240 minutes following dextrose administration.
Control animals (did not receive pravastatin) are shown in panel (a) (UYL-0, TSL-0, ORL-0). Macrobead recipients that received pravastatin
are shown in panel (b) (VPL-0, UDL-0, UVL-0). ORL-0 and UVL-0 did not receive a second porcine islet macrobead implant.

no significant differences in biochemical indices between
groups. Immunoglobulin levels were variably expressed
throughout the study with no apparent trend to associate
the findings with any particular procedure or condition.
However, IgG and IgM were elevated throughout the study
for both groups of dogs following pancreatectomy and IgA
appeared to increase approximately 2–4-fold after postimplant day 82 and remained high through the rest of the
study. Complete blood counts were determined throughout
the study (Supplementary Figure S2).

3.5. Necropsy. Complete necropsies were performed on all
study animals 29 weeks following the second macrobead
implant. During the exploration of the peritoneal cavity, it
was noted that approximately 80–90% of the macrobeads
were free-floating with the remainder of the macrobeads
primarily engulfed in either residual omentum or mesentery.

Moderate to severe coalescing proliferative lesions were noted
on the abdominal wall of all animals. These lesions were more
pronounced along the ventral aspect and within the central
portion of the abdominal wall along the incision site. Both the
dorsal and outer quarters (superior and inferior to the central
region) of the abdominal wall were less severe in nature.
Multifocal, raised, white foci were noted on the splenic
capsular surface in five animals, and scattered plaques were
limited to the splenic tail region of one dog (TSL-0). Moderate
proliferative plaques were routinely noted on the serosal
surfaces of the intestines and mesentery (Figure 4). A slight
thickening of the kidney capsule along with raised white
pinpoint foci was recorded for all six animals. Occasional
plaques were noted on the surfaces of the liver of five animals.
Overall, the proliferative lesions appeared to be limited
to the serosal surfaces, did not appear to extend into organ
parenchymal cells at sectioning, and were not thought to
impair organ function. There were no clear macroscopic
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Figure 3: Individual body weights of study animals. Open markers
indicate body weights of animals that did not receive pravastatin
(UYL-0: open triangle, TSL-0: open circle, ORL-0: open square).
Shaded markers indicate body weights of animals that did receive
pravastatin (VPL-0: triangle, UDL-0: circle, UVL-0: square). ORL-0
and UVL-0 did not receive the second macrobead implant.

differences between pravastatin and non-pravastatin-treated
animals.
3.6. Histopathology. Tissues and macrobeads collected at
necropsy were processed and examined by a board-certified
pathologist. A few viable islet cells were found in the
macrobeads from all three pravastatin-treated dogs while
no viable islet cells were found in macrobeads retrieved
from non-pravastatin-treated animals. The majority of macrobeads from both groups of dogs contained cellular debris.
Some macrobeads were surrounded by a proliferative inflammatory capsule characterized by collagenous tissue, vessels,
mesothelium, and a few inflammatory cells. Occasional
inflammatory cells were also noted along cracked surfaces
within macrobeads.
An inflammatory process characterized by fibrous tissue,
vascularization, mesothelium, and some inflammatory cells
was the most common finding from peritoneal tissues for
both groups of dogs. The inflammation presented as irregular
villous-like projections and was classified as mild to moderate
in nature (Figure 4). A chronic inflammatory process was also
associated with the serosa and subserosa of thoracic tissues
from two non-pravastatin-treated dogs (TSL-0 and UYL-0).
Thoracic tissues from two pravastatin-treated animals (UVL0 and UDL-0) were also determined to contain subserosal
inflammation. The subcapsular sinus and lymphatics of the
sternal lymph node from one dog (TSL-0) were found to
contain fragments of an inflammatory tag. Overall, the total
incidence (83.3% versus 64.3%) and total severity (22.7 versus
18.3) of inflammation on tissue surfaces were higher in the
non-pravastatin-treated group (Table 2).

4. Discussion
The results of this study are consistent with the hypothesis
that the administration of a mild anti-inflammatory agent
and an increase in the critical mass of islet tissue following
a second implant promote islet macrobead function. All dogs
were insulin-free for nine days following the first macrobead
implant, but rapidly returned to preimplant exogenous
insulin requirements. All implanted dogs, however, were

able to maintain a longer period of insulin independence
following a second macrobead implant. In addition to the
longer insulin-free period following the second implant, a
more gradual increase to preimplant insulin requirements
was observed for both groups of dogs. Importantly, this more
gradual increase in exogenous insulin was associated with
normoglycemia as well as steady or increasing body weights.
The observation that macrobead recipients gradually
returned to preimplant insulin requirements is somewhat
difficult to interpret: the preimplant insulin requirements
may not be a completely accurate guide. That is, imbalances
of glucagon secretion from the alpha cells within the islet
macrobeads and perhaps other peptides, as well as the
physiological changes and stresses induced by surgery and the
inflammatory process, may change the postimplant insulin
requirements (with or without macrobead implants). In this
light, the encapsulated islets may have been subjected to
greater insulin production demands than native pancreatic
islets.
Also notable is the finding that some animals demonstrated the ability to respond to a glucose challenge following
the second macrobead implantation. Particularly significant was the ability of VPL-0 to return to normoglycemia
during an IVGTT procedure. Although the attainment
of normoglycemia during IVGTT was significantly slower
than preinduction (2 hours versus 30 minutes) this result
clearly demonstrates the ability of porcine islet macrobeads
implanted into the peritoneal cavity to respond to a glucose
challenge. The slower response of the peritoneal islet macrobeads to restore normoglycemia is not unexpected. The
intravenous injection of glucose would likely reach vascularized native pancreatic islets sooner than encapsulated islets
free-floating in the peritoneal fluid. In addition, the slower
return to normoglycemia can be at least partially explained
by the requirements of glucose and insulin to diffuse into and
out of the agarose-agarose macrobead.
Arita et al. previously reported the ability of pravastatin to
enable the long-term restoration of normoglycemia following
the grafting of a subtherapeutic dose of autologous canine
islets [16]. Although the normoglycemic and insulin-free
period following macrobead implantation was limited in our
study, pravastatin-treated animals demonstrated improved
glucose regulation as compared to non-pravastatin-treated
animals during the period of insulin independence.
A constraint of our study is the small number of animals
in each group which limits statistical analysis. Nonetheless
the improved glucose regulation for the pravastatin group,
as reflected in the AUC analysis for both the daily blood
glucose readings and for the IVGTT at the end of the
insulin-independent period following the second implant is
apparent.
Although the majority of macrobeads were found to
be free-floating in the peritoneal cavity during the second
implant procedure and during necropsy, some macrobeads
were surrounded by a proliferative inflammatory tissue
capsule. It is not known why a few macrobeads became
enveloped in connective tissue while other beads remained
free of fibrotic tissue. The observed inflammation was limited to the serosal surfaces of peritoneal organs, suggesting
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Figure 4: Gross and microscopic images of the mesentery from two representative study animals. Small intestine and mesentery from a
control (nonpravastatin) treated animal (ORL-0; (a)) and pravastatin-treated animal (VPL-0, (b)). Microscopic images of the same tissues
from these animals are shown in (c) (ORL-0) and (d) (VPL-0). Original magnification of (c) and (d) was 200x. Scale bar is 200 𝜇m.

the macrobeads were well tolerated in the peritoneal cavity of
study animals.
There are several mechanisms that could account for
the cellular death observed within the macrobeads including
nutritional deficiency, soluble immune mediators, and inadequate islet mass. It is well known that the oxygen partial
pressure within the peritoneal cavity (40 mmHg) is considerably lower than the 100 mmHg in the arterial circulation. The
development of fibrous tissue around the macrobeads would
certainly exacerbate any oxygen deficiency. The generalized
inflammatory response observed in the peritoneal cavity of
implanted dogs would also be expected to result in the
production of inflammatory cytokines and oxygen radicals,
which have both been shown to be toxic to islets. The
small molecular size of inflammatory cytokines and oxygen
radicals such as nitric oxide and superoxide would easily
penetrate the macrobeads. Despite the transplantation of
enough islet macrobeads to provide approximately 2-3 × the
estimated exogenous insulin requirement, it is possible that
the insulin production during in vitro culture is not reflective
of insulin production in vivo, in which case an inadequate
islet mass may have been transplanted. Limitations in the
ability to administer insulin more than twice a day and in
the length of action for Humulin 70/30 could have led to an
underestimation of the exogenous insulin requirements and
thus exacerbated the possibility of implanting an inadequate
islet mass.
An enormously valuable and unique feature of the
agarose-agarose islet macrobeads is the ability to withstand

prolonged periods of in vitro culture while maintaining
cellular viability and appropriate physiological responses.
This provides the distinct opportunity to thoroughly test
the macrobeads for microbiological safety and hormone
production prior to transplantation. Appropriate numbers of
islet macrobeads producing a known amount of insulin can
thus be selected based upon individual insulin requirements.
The findings from this study support continued investigations into the transplantation of encapsulated xenogeneic islets, concurrent with pravastatin therapy, as an
option for the treatment of diabetes mellitus. The period
of reduced insulin requirements, especially following the
second implant, as well as the fasting and glucose-challenged
blood glucose levels demonstrate appropriate physiological
islet function within the agarose macrobead. The improved
macrobead function following the second implant emphasizes the requirement to achieve a critical mass of islet
tissue for optimal islet function. The biocompatibility of the
agarose-agarose islet macrobeads and the long-term health of
the study animals provide further support for this approach
to islet xenotransplantation.

Disclosure
The work described in this paper is part of the long-term
agarose-agarose porcine islet macrobead project developed
and conducted by The Rogosin Institute, a not-for-profit
clinical care and research institute affiliated with WeillCornell Medical College and The New York Presbyterian
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Table 2: Histopathology scoring.

Tissue
Heart
Lung
Diaphragm
Liver
Kidney
Spleen
Adrenal Glands
Stomach
Duodenum
Jejunum
Ileum
Mesentery
Mesenteric Lymph Node
Abdominal Wall
Total

Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity
Incidence
Severity

Nonpravastatin Control Animals
1/3 (33%)
0.3
2/3 (67%)
1.0
3/3 (100%)
2.3
2/3 (67%)
0.7
3/3 (100%)
1.7
3/3 (100%)
2.0
2/3 (67%)
0.7
3/3 (100%)
2.7
3/3 (100%)
2.7
3/3 (100%)
2.0
3/3 (100%)
2.7
3/3 (100%)
1.3
2/3 (67%)
1.0
2/3 (67%)
1.3
35/42 (83.3%)
22.7

Pravastatin-treated animals
1/3 (33%)
0.3
1/3 (33%)
0.3
3/3 (100%)
3.0
1/3 (33%)
0.7
1/3 (33%)
0.7
3/3 (100%)
1.7
2/3 (67%)
0.7
2/3 (67%)
1.3
3/3 (100%)
2.7
2/3 (67%)
1.3
3/3 (100%)
2.3
1/3 (33%)
0.7
1/3 (33%)
0.3
3/3 (100%)
2.3
27/42 (64.3%)
18.3

Severity by tissue: mean as determined by dividing sum of severity grades for each animal by number of animals in each group (3). Severity grades were 0–4
for normal, minimal, mild, moderate, and marked, respectively.
Total incidence: sum of incidence for each tissue in relation to total tissues scored.
Total severity: sum of mean severity for each tissue.
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